Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

OCS

Oculis Holding AG

Dec 11 • 04:00PM ET

16.50

Dollar change +0.15
Percentage change 0.92	%

Healthcare • Biotechnology • Switzerland • NASD

Peers: SNY VRTX PFE BMY REGN BMRN NBIX GEN RGEN EBS

| Held by: SMLV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.01	Insider Own	40.19%	Shs Outstand	41.94M	Perf Week	6.18%
Market Cap	688.80M	Forward P/E	-	EPS next Y	-2.08	Insider Trans	0.00%	Shs Float	24.37M	Perf Month	3.19%
Income	-78.83M	PEG	-	EPS next Q	-0.49	Inst Own	2.66%	Short Float	0.10%	Perf Quarter	38.08%
Sales	0.00M	P/S	-	EPS this Y	-12.51%	Inst Trans	-1.92%	Short Ratio	0.47	Perf Half Y	38.42%
Book/sh	2.69	P/B	6.13	EPS next Y	0.36%	ROA	-54.40%	Short Interest	0.02M	Perf Year	40.43%
Cash/sh	3.00	P/C	5.51	EPS next 5Y	32.37%	ROE	-69.05%	52W Range	9.60 - 18.00	Perf YTD	46.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-69.16%	52W High	-8.33%	Beta	-0.03
Dividend TTM	-	Quick Ratio	4.02	Sales past 5Y	0.00%	Gross Margin	-	52W Low	71.87%	ATR (14)	0.63
Dividend Ex-Date	-	Current Ratio	4.02	EPS Y/Y TTM	-2319.07%	Oper. Margin	-	RSI (14)	60.90	Volatility	3.89% 4.07%
Employees	36	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.14	Target Price	28.14
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-2.75%	Payout	-	Rel Volume	0.48	Prev Close	16.35
Sales Surprise	-12.54%	EPS Surprise	0.89%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	50.94K	Price	16.50
SMA20	7.36%	SMA50	6.57%	SMA200	29.37%	Trades		Volume	24,386	Change	0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-23	Initiated	Chardan Capital Markets	Buy	$30
Oct-05-23	Initiated	Stifel	Buy	$35
Jun-14-23	Initiated	BofA Securities	Buy	$22
Jun-12-23	Initiated	H.C. Wainwright	Buy	$28
Jun-08-23	Initiated	Robert W. Baird	Outperform	$58
May-10-23	Initiated	Pareto	Buy	$23
Apr-28-23	Initiated	Wedbush	Outperform	$27

Dec-06-24 04:00PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire) +5.66%
Nov-29-24 04:00AM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated (GlobeNewswire)
Nov-27-24 04:15AM	Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities (GlobeNewswire) +5.14%
Nov-13-24 04:00AM	Oculis to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-07-24 04:00AM	Oculis Reports Q3 2024 Financial Results and Provides Company Updates (GlobeNewswire)
01:04PM	Loading…
Oct-21-24 01:04PM	Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees (GlobeNewswire) +18.10%
Oct-15-24 04:00AM	Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 (GlobeNewswire)
Oct-02-24 04:00AM	Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer (GlobeNewswire)
Sep-19-24 01:00PM	Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award (GlobeNewswire)
Aug-29-24 04:00AM	Oculis to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-27-24 04:00PM	Oculis Publishes Consolidated Q2 Financial Statements and MD&A (GlobeNewswire)
04:00AM	Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update (GlobeNewswire)
Aug-15-24 08:00AM	Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer (GlobeNewswire)
Jul-30-24 04:10PM	Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.69% +6.03%
Jun-27-24 06:30AM	Oculis and EURETINA Announces the Ramin Tadayoni Award (GlobeNewswire)
05:00AM	Loading…
Jun-10-24 05:00AM	Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy (GlobeNewswire)
Jun-04-24 01:47PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
May-30-24 04:00AM	Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board (GlobeNewswire)
May-18-24 09:07AM	OCS Stock Earnings: Oculis Holding Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-17-24 04:30PM	Oculis updates share capital for its existing at-the-market offering program (GlobeNewswire)
May-08-24 04:10PM	Oculis Reports Q1 2024 Financial Results and Provides Company Updates (GlobeNewswire)
04:05PM	Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis (GlobeNewswire)
May-07-24 04:05PM	Oculis Publishes Invitation to the Annual General Meeting (GlobeNewswire)
May-06-24 06:30AM	Oculis to Present at Bank of America Global Healthcare Conference (GlobeNewswire)
Apr-29-24 04:05PM	Oculis Publishes Invitation to the Annual General Meeting (GlobeNewswire) +5.91%
Apr-22-24 09:27AM	Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market (GlobeNewswire)
Apr-11-24 08:55AM	Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market (GlobeNewswire)
Apr-10-24 06:30AM	Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development (GlobeNewswire) +6.18%
Apr-08-24 06:30AM	Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting (GlobeNewswire)
Apr-04-24 06:30AM	Oculis to Participate at Upcoming April Investor Conferences (GlobeNewswire)
06:30AM	Loading…
Mar-18-24 06:30AM	Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress (GlobeNewswire)
Feb-28-24 06:30AM	Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments (GlobeNewswire)
Feb-01-24 09:55AM	How Much Upside is Left in Oculis Holding AG (OCS)? Wall Street Analysts Think 152.77% (Zacks)
Jan-29-24 08:50AM	What Makes Oculis Holding AG (OCS) a Good Fit for 'Trend Investing' (Zacks)
06:30AM	Oculis to Present at Upcoming February Investor Conferences (GlobeNewswire)
Jan-22-24 06:30AM	Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024 (GlobeNewswire)
Jan-16-24 09:55AM	Can Oculis Holding AG (OCS) Climb 191.31% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-20-23 06:30AM	Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery (GlobeNewswire)
Dec-18-23 06:30AM	Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema (GlobeNewswire)
Dec-07-23 06:30AM	Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF Licaminlimab (OCS-02) in Dry Eye Disease (GlobeNewswire)
Nov-15-23 06:30AM	Oculis Reports Q3 2023 Financial Results and Provides Company Update (GlobeNewswire)
Nov-08-23 06:30AM	Oculis to Present at Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-23 06:30AM	Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema (GlobeNewswire) -7.14%
Oct-10-23 06:30AM	Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress (GlobeNewswire)
Oct-05-23 06:30AM	Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema (GlobeNewswire)
Sep-11-23 06:30AM	Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase (GlobeNewswire)
Aug-30-23 06:30AM	Oculis to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-29-23 06:30AM	Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update (GlobeNewswire)
Aug-08-23 06:30AM	OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery (GlobeNewswire)
Aug-02-23 08:00AM	First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema (GlobeNewswire)
Jul-26-23 08:00AM	Oculis Announces to Present at Upcoming August Investor Conferences (GlobeNewswire)
Jul-19-23 08:00AM	Oculis to Present at OIS Retina Innovation Summit (GlobeNewswire)
Jun-26-23 08:00AM	Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023 (GlobeNewswire)
Jun-13-23 04:01PM	Oculis Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares (GlobeNewswire)
Jun-12-23 08:00AM	Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile)
08:00AM	Oculis to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 11:59PM	Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares (GlobeNewswire)
May-30-23 07:06AM	Oculis Announces Launch of Proposed Public Offering of Ordinary Shares (GlobeNewswire) -7.75%
May-24-23 08:00AM	Oculis to Participate and Present at Upcoming EuDES Meeting (GlobeNewswire)
May-22-23 06:30AM	Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops (GlobeNewswire) +5.29%
May-11-23 08:00AM	Oculis Co-founders Selected as Finalists in European Inventor Award 2023 (GlobeNewswire)
Apr-26-23 07:00AM	Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs (GlobeNewswire)
Apr-05-23 07:00AM	Oculis to Participate at Upcoming Investor Conferences (GlobeNewswire)
Apr-04-23 07:00AM	Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones (GlobeNewswire)
Mar-22-23 07:00AM	Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing (GlobeNewswire) -7.01%
Mar-16-23 09:45AM	Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial (GlobeNewswire)

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCS

Oculis Holding AG

Upgrade your FINVIZ experience